Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On August 12, 2024, Satellos Bioscience Inc. (MSCLF) announced financial results for the second quarter of 2024 and provided a business update.</li><li> The company announced new data from a canine model of Duchenne muscular dystrophy (DMD) that showed treatment with SAT-3247 led to an increase in Regeneration Index, which measures the number of newly regenerated muscle fibers compared to the number of damaged and dying muscle fibers.</li><li> Satellos also recently announced the acceptance of a regulatory filing to commence a Phase 1 clinical trial of SAT-3247.</li></ul>

On August 12, 2024, Satellos Bioscience Inc. (MSCLF) announced financial results for the second quarter of 2024 and provided a business update. The company announced new data from a canine model of Duchenne muscular dystrophy (DMD) that showed treatment with SAT-3247 led to an increase in Regeneration Index, which measures the number of newly regenerated muscle fibers compared to the number of damaged and dying muscle fibers. Satellos also recently announced the acceptance of a regulatory filing to commence a Phase 1 clinical trial of SAT-3247.

MSCLF: SAT-3247 Enhances Muscle Repair in Canine Model of DMD 